We would love to hear your thoughts about our site and services, please take our survey here.
At first cursory glance, today’s announcement could seem underwhelming. But it does get SNG out there and once it starts to be used more widely, the results will speak for themselves, word will get out and people and organisations will ask for it
Also - revisiting the paper on interferons is very heartening as it discounts alpha as a competitor and doesn’t appear to mention lambda?? (Does anyone know if this is because it is type III as opposed to type 1 and perhaps behaves differently?) anyhoo.. all roads lead to beta
I was just having a little search on the Twitter and there is a fair bit of chat about Interferons by medical and academic types on the back of the recent research and science mag article. If dots are being connected at this level, one can be sure there will be a lot of activity higher up behind the scenes. And it will only take one government to go in on Synairgen and others will follow.
Very confident noises from Pharm2Farm on Twitter today. They must have a fair idea that their mask works to be putting out tweets like that. The next few days will be very interesting indeed.
If I’d known the price could go down at times I never would have invested
I was half tempted to pitch in on Twitter with something about Synairgen.. but I’m sure braver souls than I will join the interferon twitter debate and do a better job of it
Ha. No rest for the wicked - Already on the back of this latest interferon news some fans of Eiger Biopharmaceuticals are bothering doctors on Twitter about their Peginterferon Lambda - which has data out soon.
Further confirmation - if any were needed - that Synairgen has backed the right Interferon for the job
Once the peer review is out that will tell us a whole lot about the future of SNG001 and the likely partners. If the review is positive, then you would really hope that the British government would be emboldened to show their hand and level of interest. If they still held back, one might suspect some serious shenanigans and clashes of interest behind the scenes..
Can someone please point me towards the AIM companies with a predictable and constant river of positive news and an always smoothly rising SP. I have zero patience or understanding of risk/reward. Thanks
https://www.biospace.com/article/uk-s-synairgen-reports-positive-covid-19-treatment/
Found this article from July discussing/summarising the positive phase II results. Mostly stuff we’ve all read before BUT I was intrigued to read the final paragraph re: Remdesivir. Is this correct?
People have every right to sell up but why wait so long to do so? You’ve held this far and news can only be closer not further away.. I also suspect that certain big shareholders who bought in at £2 did their research and are expecting a handsome return..
?
Asking for a friend
I’m sure others have asked and answered this question but, anyone got any ideas when this peer review will be published?
And is it the next in line in the news flow?
I tell you what - I wouldn’t want to be out of this over the time period which falls between a Friday and a Monday
You could mention how the COPD results once again show that the drug is well tolerated and, crucially, that it does not clash with oral steroids
Just the other day, Graking, you said you had “shedloads of shares” in this company and but that you were unhappy with things and so you would be selling them all in the morning. .. If we assume that you are a man of your words, why are you still here? If, however, you still hold shares, then it still seems odd that you are consistently looking for angles to try and talk the company down before you sell.
That’ll be Vallance and Johnson
Even with the likely veto on naming companies, I was surprised neither Vallance nor Johnson alluded to Synairgen more directly. They could have even whispered the word interferon surely? Ho hum. What I do know is that the stock market won’t care a damn for government reticence when we get approval and/or that announcement of a partnership.